Personalized Management of Early Gynecologic Malignancies: Biomarkers, Conservative Treatment, and Survivorship

Submission Deadline: 30 November 2026 View: 32 Submit to Special Issue

Guest Editors

Prof. Ferenc Bánhidy

Email: banhidy.ferenc@semmelweis.hu

Affiliation: Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary

Homepage:

Research Interests: gynecologic oncology, clinical pharmacology

Dr. Marton Keszthelyi

Email: keszthelyi.marton@semmelweis.hu

Affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary

Homepage:

Research Interests: gynecologic oncology, cervical and endometrial cancer, systemic inflammatory and immune biomarkers, fertility-sparing treatment, conservative management of early-stage malignancies, oncologic and reproductive outcomes, personalized medicine in women's cancers

Dr. Dorottya Mühl

Email: muhl.dorottya@semmelweis.hu

Affiliation: Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary

Homepage:

Research Interests: therapy in breast cancer, neoadjuvant and adjuvant therapies, pregnancy-associated breast cancer

Dr. Richard Toth

Email: toth.richard@semmelweis.hu

Affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary

Homepage:

Research Interests: gynecologic oncology prevention, oncologic safety optimization, biomarker-driven risk assessment, targeted and adjunct therapies

Summary

Female cancers represent a rapidly evolving and highly specialized domain of clinical oncology, where advances in early detection, molecular characterization, and risk-adapted therapeutic strategies are continuously reshaping patient management. Across the disease spectrum—from early-stage to advanced malignancies—precision medicine, biomarker-driven stratification, and individualized systemic treatments are redefining standards of care. This Special Issue focuses on personalized management approaches in female cancers, with particular emphasis on gynecologic malignancies (including cervical and endometrial cancers) and breast cancer. In early-stage disease, attention is directed toward clinically applicable biomarkers, molecular classification systems, fertility-preserving and other conservative strategies, minimally invasive staging, and survivorship considerations. In advanced cancers, the issue highlights contemporary systemic treatment paradigms, including chemotherapy, endocrine therapy, immunotherapy, and targeted therapies tailored to tumor biology and predictive biomarkers. Special consideration is given to cancer during pregnancy, addressing the complex balance between optimal maternal oncologic outcomes and fetal safety, and to multidisciplinary decision-making in this unique clinical context. By bringing together translational research, clinical trials, and outcomes-focused investigations, this Special Issue aims to strengthen evidence-based, personalized care across the continuum of female cancers—integrating molecular innovation, systemic treatment advances, and survivorship principles to improve both survival and quality of life.

Keywords